Literature DB >> 15708381

The N-terminal membrane anchor domain of the membrane-bound prostacyclin synthase involved in the substrate presentation of the coupling reaction with cyclooxygenase.

Ke-He Ruan1, Hui Deng, Jiaxin Wu, Shui-Ping So.   

Abstract

To mimic the native conditions, the cyclooxygenase (COX)/prostaglandin I(2) synthase (PGIS) coupling reaction system was used to determine the coordination of PGIS with COX for the biosynthesis of prostacyclin (PGI(2)) using arachidonic acid (AA) as a substrate in a membrane-bound environment. The membrane-bound PGIS exhibited a faster isomerization of PGH(2) produced by COX to PGI(2) than the detergent-solubilized PGIS. To determine whether the N-terminal domain of PGIS responds to the facilitation of PGH(2) movement (presentation) from COX to the active site of PGIS, the first 20 residues of PGIS (Delta20-PGIS) were deleted and expressed in COS-7 cells. Delta20-PGIS retained membrane-bound properties and exhibited a slower substrate presentation property. Furthermore, a chimeric molecule (PGIS/TXAS(8-27)) with the replacement of the first 20 residues of PGIS by the corresponding membrane anchor region (residues 8-27) of thromboxane A(2) synthase was created to evaluate the mechanism influencing the biosynthesis of PGI(2) in coordination with COX. The chimera revealed a multiple fold delay in the PGH(2) presentation in low range concentrations of AA (0.3-3muM) at 30s reactions. However, the delay could be recovered by a longer incubation time in high range concentrations of AA (>10muM), but not in low range concentrations of AA. These results demonstrated that the N-terminal domain of PGIS plays a role in the facilitation of the substrate presentation to the PGIS active site in low concentrations of AA, which may be a physiological condition. The TXAS N-terminal domain could not replace the function of the corresponding domain of PGIS, indicating that the facilitation of the substrate presentation is specific.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15708381     DOI: 10.1016/j.abb.2004.12.018

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  7 in total

1.  Inducible COX-2 dominates over COX-1 in prostacyclin biosynthesis: mechanisms of COX-2 inhibitor risk to heart disease.

Authors:  Cheng-Huai Ruan; Shui-Ping So; Ke-He Ruan
Journal:  Life Sci       Date:  2010-10-28       Impact factor: 5.037

Review 2.  Prostacyclin therapy for pulmonary arterial hypertension.

Authors:  Cheng-Huai Ruan; Richard A F Dixon; James T Willerson; Ke-He Ruan
Journal:  Tex Heart Inst J       Date:  2010

3.  Dichotomous effects of aryl hydrocarbon receptor (AHR) activation on human fetoplacental endothelial cell function.

Authors:  Anna Palatnik; Hong Xin; Emily J Su
Journal:  Placenta       Date:  2016-06-11       Impact factor: 3.481

4.  Modifications in the N-terminus of an insect cytochrome P450 enhance production of catalytically active protein in baculovirus-Sf9 cell expression systems.

Authors:  Wenfu Mao; May R Berenbaum; Mary A Schuler
Journal:  Insect Biochem Mol Biol       Date:  2007-09-26       Impact factor: 4.714

5.  Engineering of a novel hybrid enzyme: an anti-inflammatory drug target with triple catalytic activities directly converting arachidonic acid into the inflammatory prostaglandin E2.

Authors:  Ke-He Ruan; Vanessa Cervantes; Shui-Ping So
Journal:  Protein Eng Des Sel       Date:  2009-10-22       Impact factor: 1.650

6.  Large-scale expression, purification, and characterization of an engineered prostacyclin-synthesizing enzyme with therapeutic potential.

Authors:  Ke-He Ruan; Shui-Ping So; Hanjing Wu; Vanessa Cervantes
Journal:  Arch Biochem Biophys       Date:  2008-09-22       Impact factor: 4.013

7.  A novel single-chain enzyme complex with chain reaction properties rapidly producing thromboxane A2 and exhibiting powerful anti-bleeding functions.

Authors:  Yan Li; Qun-Ying Li; Qing-Lan Ling; Shui-Ping So; Ke-He Ruan
Journal:  J Cell Mol Med       Date:  2019-10-19       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.